Cost effectiveness of a novel SwaRSA Strategy to reduce acute exacerbations of COPD
Published in Neuroscience, Protocols & Methods, and General & Internal Medicine
The paper discusses the significant economic burden of Chronic Obstructive Pulmonary Disease (COPD) and the potential cost savings from reducing COPD exacerbations. A decision analytic model that evaluates the cost-effectiveness of a Swallowing and Respiratory Sensation Assessment (SwaRSA) strategy, involving swallowing and respiratory sensation assessment tests and subsequent swallowing rehabilitation, is presented to reduce COPD exacerbations. The model suggests that self-assessment with the Eating Assessment Tool (EAT-10) and subsequent intervention is a highly cost-effective option compared to no-SwaRSA.
Key Points: Novel SwaRSA Decision Analytic Model; Epiu I. et al 2025 https://pubmed.ncbi.nlm.nih.gov/40200355/
Economic Burden of COPD
- COPD represents a considerable economic burden globally, with an estimated cost of US$ 2.1 trillion.
- Annual COPD costs in the USA are expected to increase to 40 billion USD per year.
- Australia spent about AUD$ 831.6 million in 2020-21 on the management of COPD, with over half of this cost for hospital care.
Potential for Cost Savings
- A significant portion of the COPD management cost could be avoided by reducing exacerbations.
Cost-Effectiveness of SwaRSA Strategy
- The decision analytic model assessed the cost-effectiveness of a Swallowing and Respiratory Sensation Assessment (SwaRSA) strategy, which involved swallowing and respiratory sensation assessment tests and subsequent swallowing rehabilitation.
- Three individual testing strategies within the SwaRSA approach were found to be cost-effective, with incremental cost-effectiveness ratios per QALY ranging from $27,000 to $37,000 AUD.
- The EAT-10 and the tongue strength were the two dominant options on the cost-effectiveness frontier.
- The model results were robust to variations in one-way and probabilistic sensitivity analyses, and the self-assessment with the EAT-10 and subsequent intervention was highly cost-effective relative to no-SwaRSA.
Here are the key implications of the findings for healthcare policy regarding COPD management:
-
The high economic burden of COPD, estimated at over $2 trillion globally and $40 billion annually in the US, highlights the need for more effective and cost-efficient management strategies.
-
Novel finding that a significant portion of COPD costs could be avoided by reducing exacerbations suggests that interventions targeting exacerbation prevention should be a priority for policymakers.
-
The high prevalence of swallowing difficulties (dysphagia) among COPD patients, affecting up to 56% of hospitalized patients, suggests that screening and management of swallowing disorders should be integrated into standard COPD care.
-
This cost-effectiveness analysis of the SwaRSA strategy, which includes swallowing and respiratory sensation assessment tests followed by swallowing rehabilitation, provides strong evidence that such an approach can be a highly cost-effective way to reduce COPD exacerbations and associated costs.
-
Further research may be needed to validate these findings in different healthcare settings and populations, but the current evidence suggests that integrating swallowing assessment and rehabilitation into COPD management should be a priority for healthcare policy
Follow the Topic
-
BMC Pulmonary Medicine
This journal is an open access, peer-reviewed journal that considers articles on all aspects of the prevention, diagnosis and management of pulmonary and associated disorders, as well as related molecular genetics, pathophysiology, and epidemiology.
Related Collections
With collections, you can get published faster and increase your visibility.
Artificial intelligence and machine learning: applications in pulmonary medicine
BMC Pulmonary Medicine is calling for submissions to our Collection on Artificial intelligence and machine learning: applications in pulmonary medicine. Advancements in artificial intelligence (AI) and machine learning (ML) have the potential to revolutionize pulmonary medicine by enabling innovative approaches to diagnosis, treatment, and prevention of pulmonary disorders. In this era of rapid technological advancements, AI can assist in early detection, risk assessment, and prognostic evaluation by analyzing large datasets, thus leading to improved patient outcomes and better management strategies.
BMC Pulmonary Medicine is launching this collection in alignment with the United Nations' Sustainable Development Goals (SDGs) 3: Good health and well-being and SDG 10: Reduced inequalities. The aim of this collection is to consolidate both fundamental and clinical research to advance our comprehension of pulmonary disorders.
BMC Pulmonary Medicine welcomes original research on the design, implementation, optimization, and clinical impact of AI applications in the field of pulmonary medicine. Topics of interest include, but are not limited to, the following:
• Machine learning (ML) algorithms for early detection of pulmonary diseases
• AI applications for diagnostic accuracy studies
• AI systems as an intervention in live clinical settings
• Predictive modeling using AI for personalized risk assessment of pulmonary disorders
• Application of AI in pulmonary imaging analysis
• Utilizing natural language processing and AI for analyzing electronic health records in pulmonary care
• Exploring the potential of AI in optimizing pulmonary surgical procedures
• Wearable devices and AI algorithms for continuous monitoring of pulmonary health
• AI-enabled precision medicine approaches for personalized treatment
• AI-powered automated risk scoring systems for exacerbations of pulmonary diseases
• Ethical considerations and challenges in the implementation of AI in pulmonary medicine
We encourage the use of standardized reporting guidelines for research with AI/ ML components to encourage authors to provide information to allow their work to be evaluated appropriately. Reporting guidelines and checklists have been developed for a broad range of study design and research types with AI/ML components.
Publishing Model: Open Access
Deadline: Jul 29, 2025
Aging and lung disease
BMC Pulmonary Medicine calls for submissions to our Collection on Aging and lung disease. The aging process is associated with physiological changes in the respiratory system, leading to an increased susceptibility to lung diseases such as chronic obstructive pulmonary disease (COPD), interstitial lung disease, and lung cancer. Additionally, age-related alterations in the immune system, including inflammaging and cellular senescence, contribute to the pathogenesis of lung diseases. Understanding the complex interplay between aging and lung disease is crucial for developing effective strategies for prevention, diagnosis, and management.
Continued advancement of our collective understanding in this area is essential for addressing the growing burden of lung diseases in aging populations. Recent advances have elucidated the molecular mechanisms underlying inflammaging and senescence in the context of lung disease, paving the way for the development of novel therapeutic approaches targeting these processes. Furthermore, research has highlighted the impact of aging on the susceptibility to respiratory infections and the development of lung cancer, emphasizing the need for tailored interventions for older adults.
This Collection supports and amplifies research related to SDG 3: Good Health and Well-being and SDG 10: Reduced Inequalities. Topics might include but are not limited to:
• Inflammaging and its impact on lung health
• Senolytics and their potential in treating age-related lung diseases
• Age-related changes in the lung microenvironment
• Respiratory infections in aging populations
• Lung cancer in the context of aging
Publishing Model: Open Access
Deadline: Jul 08, 2025
Please sign in or register for FREE
If you are a registered user on Research Communities by Springer Nature, please sign in